Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.
Journal
Antiviral therapy
ISSN: 2040-2058
Titre abrégé: Antivir Ther
Pays: England
ID NLM: 9815705
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
14
03
2021
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
7
5
2022
Statut:
ppublish
Résumé
The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who had treatment modifications after failure. Treatment modification was defined as a change of two antiretrovirals, a drug class change or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 changes and undetectable viral load (UVL <1,000 copies/ml) at 1 year after second-line failure using linear and logistic regression, respectively. Survival time was analysed using competing risk regression. Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a subsequent treatment modification. Compared with those who continued the failing regimen, the average CD4 cell increase was higher in patients who had a modification without TI (difference =77.5, 95% CI 35.3, 119.7) while no difference was observed among those with TI (difference =-5.3, 95% CI -67.3, 56.8). Compared with those who continued the failing regimen, the odds of achieving UVL was lower in patients with TI (OR=0.18, 95% CI 0.06, 0.60) and similar among those who had a modification without TI (OR=1.97, 95% CI 0.95, 4.10), with proportions of UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications. CD4 cell improvements were observed in those who had treatment modification without TI compared with those on the failing regimen. When no other options are available, maintaining the same failing ART combination provided better VL control than interrupting treatment.
Sections du résumé
BACKGROUND
The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who had treatment modifications after failure.
METHODS
Treatment modification was defined as a change of two antiretrovirals, a drug class change or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 changes and undetectable viral load (UVL <1,000 copies/ml) at 1 year after second-line failure using linear and logistic regression, respectively. Survival time was analysed using competing risk regression.
RESULTS
Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a subsequent treatment modification. Compared with those who continued the failing regimen, the average CD4 cell increase was higher in patients who had a modification without TI (difference =77.5, 95% CI 35.3, 119.7) while no difference was observed among those with TI (difference =-5.3, 95% CI -67.3, 56.8). Compared with those who continued the failing regimen, the odds of achieving UVL was lower in patients with TI (OR=0.18, 95% CI 0.06, 0.60) and similar among those who had a modification without TI (OR=1.97, 95% CI 0.95, 4.10), with proportions of UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications.
CONCLUSIONS
CD4 cell improvements were observed in those who had treatment modification without TI compared with those on the failing regimen. When no other options are available, maintaining the same failing ART combination provided better VL control than interrupting treatment.
Identifiants
pubmed: 33843656
doi: 10.3851/IMP3388
pmc: PMC8275121
mid: NIHMS1717472
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-387Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Références
J Acquir Immune Defic Syndr. 2020 May 1;84(1):107-113
pubmed: 32032304
Trop Med Int Health. 2018 Oct;23(10):1075-1083
pubmed: 30058269
AIDS Res Ther. 2018 Apr 10;15(1):10
pubmed: 29636106
AIDS. 2012 May 15;26(8):929-38
pubmed: 22313953
BMC Infect Dis. 2017 Aug 22;17(1):582
pubmed: 28830382
Trop Med Int Health. 2016 Sep;21(9):1131-7
pubmed: 27383454
AIDS. 2014 Sep 10;28(14):2097-107
pubmed: 24977440
AIDS Res Hum Retroviruses. 2016 Aug;32(8):772-81
pubmed: 27030657
HIV Med. 2010 Jan;11(1):31-9
pubmed: 19601993
PLoS One. 2020 Sep 28;15(9):e0239191
pubmed: 32986756
Glob Health Action. 2017;10(1):1290916
pubmed: 28594295
PLoS One. 2014 Sep 15;9(9):e106887
pubmed: 25221931
Antivir Ther. 2016;21(6):517-527
pubmed: 26961354
PLoS One. 2019 Nov 21;14(11):e0225631
pubmed: 31751433
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):73-78
pubmed: 30334876
Glob Health Action. 2014 Jul 30;7:24861
pubmed: 25084835
PLoS One. 2020 Mar 2;15(3):e0228601
pubmed: 32119663
AIDS Patient Care STDS. 2017 May;31(5):205-212
pubmed: 28445088
Am J Pathol. 2018 Mar;188(3):683-695
pubmed: 29253459
AIDS Care. 2018 Jul;30(7):863-870
pubmed: 29463102
Open Forum Infect Dis. 2018 Feb 02;5(2):ofy005
pubmed: 29435471
Lancet HIV. 2019 Nov;6(11):e750-e759
pubmed: 31601544
Lancet HIV. 2019 Sep;6(9):e588-e600
pubmed: 31371262